Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for the viruses.
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
Collaboration will investigate a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors (GIST).
Columbia University researchers have created a user-friendly program that rapidly predicts which genes are implicated in an individual’s cancer and recommends treatments.
In a phase 1 study, eight out of 12 patients with relapsed and/or refractory blood cancers responded to a combination of two common chemotherapy drugs.
Dr. Drake studies the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer.
Adding a new drug called olaratumab to traditional chemotherapy increased survival in sarcoma patients, researchers at Columbia University Medical Center have found.
The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.